Report overview
Meningococcal disease is a severe infection of meninges, the thin layers of tissue covering brain and spinal cord, caused by the bacteria Neisseria meningitidis. This bacteria can also cause bloodstream infections (septicemia). Bacterial meningitis is severe because of rapid onset and a significant risk of death associated with infection. Infection of Neisseria meningitidis may also result in mental retardation, deafness and epilepsy. 12 strains of N. meningitidis have been identified, 6 of which (A, B, C, W, X and Y) are capable enough to cause epidemics. Meningococcal septicaemia is a rare but fatal form of meningococcal disease characterized by a haemorrhagic rash and rapid circulatory collapse.
This report aims to provide a comprehensive presentation of the global market for Meningococcal Disease Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Meningococcal Disease Drugs. This report contains market size and forecasts of Meningococcal Disease Drugs in global, including the following market information:
Global Meningococcal Disease Drugs Market Revenue, 2018-2023, 20242035, ($ millions)
Global Meningococcal Disease Drugs Market Sales, 2018-2023, 20242035, (Kiloton)
Global top five Meningococcal Disease Drugs companies in 2022 (%)
The global Meningococcal Disease Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Injectable Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Meningococcal Disease Drugs include Pfizer, GlaxoSmithKline, Sanofi Pasteur, Novartis, Merck Sharp & Dohme, Hebei Hejia Pharmaceutical Technology Group Co., Ltd, Shandong Jincheng Pharmaceutical Group Co.,ltd., Apeloa Pharmaceutical Co.,Ltd. and Yiling Pharmaceutical, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Meningococcal Disease Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Meningococcal Disease Drugs Market, by Type, 2018-2023, 20242035 ($ Millions) & (Kiloton)
Global Meningococcal Disease Drugs Market Segment Percentages, by Type, 2022 (%)
Injectable
Oral
Global Meningococcal Disease Drugs Market, by Application, 2018-2023, 20242035 ($ Millions) & (Kiloton)
Global Meningococcal Disease Drugs Market Segment Percentages, by Application, 2022 (%)
Hospitals
Drugstores
Others
Global Meningococcal Disease Drugs Market, By Region and Country, 2018-2023, 20242035 ($ Millions) & (Kiloton)
Global Meningococcal Disease Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Meningococcal Disease Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Meningococcal Disease Drugs revenues share in global market, 2022 (%)
Key companies Meningococcal Disease Drugs sales in global market, 2018-2023 (Estimated), (Kiloton)
Key companies Meningococcal Disease Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
GlaxoSmithKline
Sanofi Pasteur
Novartis
Merck Sharp & Dohme
Hebei Hejia Pharmaceutical Technology Group Co., Ltd
Shandong Jincheng Pharmaceutical Group Co.,ltd.
Apeloa Pharmaceutical Co.,Ltd.
Yiling Pharmaceutical
Baiyunshan Pharmaceutical
SSY Group Limited
Lukang Pharmaceutical Co.,Ltd.
North China Pharmaceutical Company Ltd.
Harbin Pharmaceutical Group Co.,Ltd.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Meningococcal Disease Drugs, market overview.
Chapter 2: Global Meningococcal Disease Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Meningococcal Disease Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Meningococcal Disease Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Meningococcal Disease Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
